This morning, Allergy Therapeutics has announced a strong trading update for the first four months of 2016 (+12% like-for-like constant currency growth, or +15% including the Alerpharma acquisition which was completed June 2015) which, considering the flat market backdrop and the reported FY15 constant currency sales growth of 11%, represents a robust performance. In this context, the company has announced the proposed placing via accelerated bookbuild to raise up to £12m which will be

17 Nov 2015
Panmure Morning Note 17-11-15

Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Panmure Morning Note 17-11-15
Allergy Therapeutics plc (AGY:LON) | 6.0 0 9.9% | Mkt Cap: 286.0m
- Published:
17 Nov 2015 -
Author:
Dr Mike Mitchell -
Pages:
3 -
This morning, Allergy Therapeutics has announced a strong trading update for the first four months of 2016 (+12% like-for-like constant currency growth, or +15% including the Alerpharma acquisition which was completed June 2015) which, considering the flat market backdrop and the reported FY15 constant currency sales growth of 11%, represents a robust performance. In this context, the company has announced the proposed placing via accelerated bookbuild to raise up to £12m which will be